Nimbus Therapeutics Inc., of Cambridge, Mass., completed an oversubscribed $43 million series B financing led by Pfizer Venture Investments and Lightstone Ventures. All of the company's series A investors, including Atlas Venture, SR One, Lilly Ventures, and Bill Gates, also participated in the series B round.